Study summary
Fenebrutinib cut relapses by about half compared with an existing pill
51%fewer relapses than teriflunomide
What was tested
Fenebrutinib, a pill that blocks the BTK enzyme in immune cells, against teriflunomide, an established MS pill, in relapsing MS.
What they found
- Relapses were 51% lower than with teriflunomide in FENhance 1.
- Pooling both trials, the relapse rate was 55% lower over 96 weeks.
- The FDA has been reported to be reviewing it for both relapsing and primary progressive MS.
What it means
The first of its drug class to succeed in relapsing MS in phase 3.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.